Amyloidosis Treatment Market Size, Share & Trends Analysis Report By Treatment (Stem Cell Transplant, Chemotherapy, Supportive Care, Surgery, Targeted Therapy), By Country, And Segment Forecasts, 2018 - 2025

Published: Sep, 2018 | Pages: 73 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global amyloidosis treatment market size is expected to reach USD 6.7 billion by 2025, according to a new report by Grand View Research, Inc., registering a 7.2% CAGR during the forecast period. Several factors such as increased adoption of novel targeted therapies and transplantations, emergence of biologics, and rising geriatric population are driving the market.

Amyloidosis is a group of rare diseases where misfolded aggregates of proteins (amyloids) buildup in tissues and organs. AL amyloidosis is the most common type of amyloidosis in U.S., with approximately 3,000 to 4,000 new cases diagnosed annually. Although in majority of cases, the disease is diagnosed in people over the age of 60, there are a few cases of people being diagnosed in their late 20s and about two-thirds of the patients are male.

Among treatments, chemotherapy held the largest share in 2017, followed by targeted therapy, and supportive care. However, targeted therapies are expected to dominate the market in 2025, supported by a strong pipeline and potential approval of drugs such as Alnylam's Onpattro, Ionis' Tegsedi, Johnson & Johnson's Darzalex, and Takeda's Ninlaro.

Stem cell transplants and targeted therapies are gaining traction in developed countries. However, amyloidosis cohorts in endemic regions do not have access to sufficient healthcare infrastructure to ensure prompt diagnosis and treatment in underdeveloped countries. Chemotherapy and supportive care are anticipated to lose market share over the forecast period due to adverse side effects and lower efficacy.

Further key findings from the report suggest:

• An estimated 16,000 people in U.S. suffer from amyloidosis, with approximately 3,000 to 4,000 new cases being reported annually

• U.S. dominated the global amyloidosis treatment market, with a share of more than 27.0% in 2017 due to potential launch of pipeline drugs, increased adoption of novel therapeutics, and high cost of treatment in the country

• Chemotherapy dominated the amyloidosis treatment market, with a share of about 35.0% in 2017. Targeted therapies are projected to witness double-digit growth during the forecast period due to multiple product approvals

• Emerging markets for amyloidosis such as China, Sweden, Portugal, Turkey, South Africa, Brazil, Mexico, Saudi Arabia, and India are expected to show attractive growth over the forecast period due to improved healthcare infrastructure, favorable government policies, increased investment, and large amyloidosis cohort• Alnylam, Ionis, Pfizer, Johnson & Johnson and Takeda are some of the key players operating in this market

• Currently, 19 products are under evaluation for amyloidosis treatment in various stages of clinical development. Promising pipeline candidates such as Onpattro, Vyndaqel, Tegsedi, Darzalex, and Ninlaro are expected to generate significant revenue upon launch.

 Table of Contents

Chapter 1 Report Scope
                   1.1 Treatment Scope
                   1.2 Country Scope
                   1.3 Estimates and Forecast Timeline

Chapter 2 Methodology
                   2.1 Research Methodology
                       2.1.1 Information procurement
                   2.2 Information or Data Analysis
                   2.3 Market Formulation & Validation
                   2.4 List of Sources
                   2.5 List of Abbreviations

Chapter 3 Objectives
                   3.1 Objective - 1: Understanding the market dynamics
                   3.2 Objective - 2: Understanding the trends & variables in the individual countries
                   3.3 Objective - 3: Understanding the attributes such as strategy framework
                   3.4 Objective - 4: Understanding the key service and application scopes

Chapter 4 Executive Summary

Chapter 5 Disease Primer and Epidemiology
                   5.1 Disease Primer
                       5.1.1 Types
                           5.1.1.1 AL Amyloidosis
                           5.1.1.2 AA Amyloidosis
                           5.1.1.3 Transthyretin Amyloidosis (ATTR)
                       5.1.2 Diagnosis
                   5.2 Epidemiology
                       5.2.1 Current Prevalence and Incidence for Seven Major Markets (U.S., Japan, EU5)
                       5.2.2 Forecast Prevalence and Incidence for Seven Major Markets (U.S., Japan, EU5)
                           5.2.2.1 U.S.
                           5.2.2.2 Japan
                           5.2.2.3 U.K.
                           5.2.2.4 Germany
                           5.2.2.5 France
                           5.2.2.6 Spain
                           5.2.2.7 Italy

Chapter 6 Global Amyloidosis Market Overview
                   6.1 Market, by Treatment
                       6.1.1 Chemotherapy
                       6.1.2 Supportive Care
                       6.1.3 Surgery
                       6.1.4 Stem Cell Transplant (SCT)
                       6.1.5 Targeted Therapy
                   6.2 Market, by Country
                       6.2.1 U.S.
                       6.2.2 Japan
                       6.2.3 U.K.
                       6.2.4 Germany
                       6.2.5 France
                       6.2.6 Spain
                       6.2.7 Italy
                       6.2.8 RoW
                   6.3 Market Size & Forecast
                       6.3.1 Sales Performance
                           6.3.1.1 Sales Performance, by Treatment (2017 - 2025)
                           6.3.1.2 Sales Performance, by Country (2017 - 2025)
                   6.4 Amyloidosis Market: Drivers and Restraints
                   6.5 M&A, Deal Landscape (2014-2018 YTD)
                   6.6 SWOT

Chapter 7 Global Amyloidosis Market: Pipeline Intelligence
                   7.1 Pipeline Landscape
                       7.1.1 Leading Drugs in Development
                       7.1.2 Key R&D Trends
                   7.2 Promising Drug Candidates in Pipeline
                       7.2.1 Late Stage Pipeline Analysis
                       7.2.2 Profile of Disruptive Drugs
                           7.2.2.1 Vyndaqel (tafamidis)
                           7.2.2.2 Onpattro (patisiran)
                           7.2.2.3 Tegsedi (inotersen)
                           7.2.2.4 Darzalex (daratumumab)
                           7.2.2.6 Ninlaro (ixazomib)
                           7.2.2.7 GSK2398852 (dezamizumab)
                           7.2.2.8 Pomalyst (pomalidomide)
                           7.2.2.9 ALN-TTRsc02
                           7.2.2.10 CAEL101
                   7.3 Global Pipeline Forecast

Chapter 8 Company Profiles
                   8.1 Pfizer
                       8.1.1 Company Overview
                       8.1.2 Current Product Portfolio - Major Products
                       8.1.3 Product Forecast Sales up to 2025
                       8.1.4 Strategic Initiatives
                           8.1.4.1 Key Company News Flow
                       8.1.5 SWOT
                   8.2 Ionis Pharmaceuticals
                       8.2.1 Company Overview
                       8.2.2 Current Product Portfolio - Major Products
                       8.2.3 Product Forecast Sales up to 2025
                       8.2.4 Strategic Initiatives
                           8.2.4.1 Key Company News Flow
                       8.2.5 SWOT
                   8.3 Alnylam Pharmaceuticals
                       8.3.1 Company Overview
                       8.3.2 Current Product Portfolio - Major Products
                       8.3.3 Product Forecast Sales up to 2025
                       8.3.4 Strategic Initiatives
                           8.3.4.1 Key Company News Flow
                       8.3.5 SWOT
                   8.4 Johnson & Johnson
                       8.4.1 Company Overview
                       8.4.2 Current Product Portfolio - Major Products
                       8.4.3 Strategic Initiatives
                           8.4.3.1 Key Company News Flow
                       8.4.4 SWOT
                   8.5 Takeda
                       8.5.1 Company Overview
                       8.5.2 Current Product Portfolio - Major Products
                       8.5.3 Strategic Initiatives (Takeda)
                           8.5.3.1 Key Company News Flow
                       8.5.4 SWOT

Chapter 9 Market Outlook
                   9.1 Winners and Losers
                   9.2 Emerging Companies
                       9.2.1 Eidos Therapeutics
                       9.2.2 Corino Therapeutics
                       9.2.3 GlaxoSmithKline
                       9.2.4 Prothena
                       9.2.5 Caelum Biosciences
                   9.3 What the Future Holds

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 Forecast Amyloidosis Prevalence and Incidence, 2017 - 2025
Table 4 Sales Performance, by Treatment (in $ Million)
Table 5 Sales Performance, by Country (in $ Million)
Table 6 Amyloidosis R&D Pipeline - Drugs in Development
Table 7 R&D Pipeline Overview
Table 8 Late Stage Pipeline
Table 9 Product Profile: Vyndaqel (tafamidis)
Table 10 Product Profile: Onpattro (patisiran)
Table 11 Product Profile: Tegsedi (inotersen)
Table 12 Product Profile: Darzalex (daratumumab)
Table 13 Product Profile: Ninlaro (ixazomib)
Table 14 Product Profile: GSK2398852 (dezamizumab)
Table 15 Product Profile: Pomalyst (pomalidomide)
Table 16 Product Profile: ALN-TTRsc02
Table 17 Product Profile: CAEL101
Table 18 Global Pipeline Forecast
Table 19 Product Portfolio: Vyndaqel
Table 20 Vyndaqel Sales Forecast, 2017 - 2025 (in $ Million)
Table 21 Product Portfolio: Tegsedi
Table 22 Tegsedi Sales Forecast, 2017 - 2025 (in $ million)
Table 23 Product Portfolio: Onpattro
Table 25 Product Portfolio: ALN-TTRsc02
Table 26 Onpattro Sales Forecast, 2017 - 2025 (in $ million)
Table 27 Product Portfolio: Darzalex (daratumumab)
Table 28 Darzalex Sales Forecast, 2017 - 2025 (in $ million)
Table 29 Product Portfolio: Ninlaro (ixazomib)
Table 30 Ninlaro Sales Forecast, 2017 - 2025 (in $ million)

List of Figures

Fig.1 Market research process
Fig.2 Information procurement
Fig.3 Primary research pattern
Fig.4 Market research approaches
Fig.5 Value chain based sizing & forecasting
Fig.6 QFD modelling for market share assessment
Fig.7 Market formulation & validation
Fig.8 Amyloidosis Treatment Market Segmentation
Fig.9 Amyloidosis Treatment Market Outlook: Key Takeaways
Fig.10 Current Amyloidosis Prevalence Across Seven Major Markets - 2017
Fig.11 Current Amyloidosis Incidence Across Seven Major Markets - 2017
Fig.12 U.S. Forecast Sickle Cell Disease Prevalence (2017 - 2025)
Fig.13 Japan Forecast Sickle Cell Disease Prevalence (2017 - 2025)
Fig.14 U.K. Forecast Sickle Cell Disease Prevalence (2017 - 2025)
Fig.15 Germany Forecast Sickle Cell Disease Prevalence (2017 - 2025)
Fig.16 France Forecast Sickle Cell Disease Prevalence (2017 - 2025)
Fig.17 Spain Forecast Sickle Cell Disease Prevalence (2017 - 2025)
Fig.18 Italy Forecast Sickle Cell Disease Prevalence (2017 - 2025)
Fig.19 Amyloidosis Market Share, by Treatment (2017 & 2025)
Fig.20 Amyloidosis Market Share, by Country (2017 & 2025)
Fig.21 U.S. Amyloidosis Treatment Market, $ Million (2017 - 2025)
Fig.22 Japan Amyloidosis Treatment Market, $ Million (2017 - 2025)
Fig.23 U.K. Amyloidosis Treatment Market, $ Million (2017 - 2025)
Fig.24 Germany Amyloidosis Treatment Market, $ Million (2017 - 2025)
Fig.25 France Amyloidosis Treatment Market, $ Million (2017 - 2025)
Fig.26 Spain Amyloidosis Treatment Market, $ Million (2017 - 2025)
Fig.27 Italy Amyloidosis Treatment Market, $ Million (2017 - 2025)
Fig.28 RoW Amyloidosis Treatment Market, $ Million (2017 - 2025)
Fig.29 Amyloidosis Market Size & Forecast, $ Million (2017 - 2025)
Fig.30 Global Amyloidosis Market SWOT
Fig.31 SWOT Analysis (Pfizer)
Fig.32 SWOT Analysis (Ionis Pharmaceuticals)
Fig.33 SWOT Analysis (Alnylam Pharmaceuticals)
Fig.34 SWOT Analysis (Johnson & Johnson)
Fig.35 SWOT Analysis (Takeda)